[go: up one dir, main page]

FR2847267B1 - Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2 - Google Patents

Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2

Info

Publication number
FR2847267B1
FR2847267B1 FR0214490A FR0214490A FR2847267B1 FR 2847267 B1 FR2847267 B1 FR 2847267B1 FR 0214490 A FR0214490 A FR 0214490A FR 0214490 A FR0214490 A FR 0214490A FR 2847267 B1 FR2847267 B1 FR 2847267B1
Authority
FR
France
Prior art keywords
activity
phospholipase
inhibiting
testing
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0214490A
Other languages
English (en)
Other versions
FR2847267A1 (fr
Inventor
Delphine Rival
Sebastien Bonnet
Eric Perrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Beauty Care Solutions France SAS
Original Assignee
Coletica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32187745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2847267(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coletica SA filed Critical Coletica SA
Priority to FR0214490A priority Critical patent/FR2847267B1/fr
Priority to US10/365,897 priority patent/US20040096925A1/en
Priority to CH00269/03A priority patent/CH694107A5/fr
Priority to JP2003048891A priority patent/JP2004166684A/ja
Priority to KR20030017869A priority patent/KR101172700B1/ko
Priority to DE2003120603 priority patent/DE10320603A1/de
Priority to DE10362194.6A priority patent/DE10362194C5/de
Publication of FR2847267A1 publication Critical patent/FR2847267A1/fr
Publication of FR2847267B1 publication Critical patent/FR2847267B1/fr
Application granted granted Critical
Priority to JP2009032657A priority patent/JP5425489B2/ja
Priority to JP2012168187A priority patent/JP2012224637A/ja
Priority to US14/585,256 priority patent/US20150110907A1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
FR0214490A 2002-11-19 2002-11-19 Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2 Expired - Lifetime FR2847267B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR0214490A FR2847267B1 (fr) 2002-11-19 2002-11-19 Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2
US10/365,897 US20040096925A1 (en) 2002-11-19 2003-02-12 Method of testing the activity of a potentially active substance to inhibit the enzymatic activity of phospholipase A2
CH00269/03A CH694107A5 (fr) 2002-11-19 2003-02-20 Procédé de test pour la recherche et l'identification d'une substance potentiellement active pour inhiber l'activité enzymatique de la phospholipase A2
JP2003048891A JP2004166684A (ja) 2002-11-19 2003-02-26 ホスホリパーゼａ２の酵素活性を阻害するのに有効である可能性がある物質の活性の試験方法
KR20030017869A KR101172700B1 (ko) 2002-11-19 2003-03-21 포스포리파아제 ａ2의 효소활성을 억제하기 위한 잠재적활성물질의 활성 검사방법
DE10362194.6A DE10362194C5 (de) 2002-11-19 2003-05-08 Verfahren zum Testen der Aktivität einer möglichen wirksamen Substanz, die die enzymatische Aktivität der Phospholipase A2 hemmen kann
DE2003120603 DE10320603A1 (de) 2002-11-19 2003-05-08 Verfahren zum Testen der Aktivität einer möglichen wirksamen Substanz, die die enzymatische Aktivität der Phospholipase A2 hemmen kann
JP2009032657A JP5425489B2 (ja) 2002-11-19 2009-02-16 ホスホリパーゼａ２の酵素活性を阻害するのに有効である可能性がある物質の活性の試験方法
JP2012168187A JP2012224637A (ja) 2002-11-19 2012-07-30 ホスホリパーゼａ２の酵素活性を阻害するのに有効である可能性がある物質の活性の試験方法
US14/585,256 US20150110907A1 (en) 2002-11-19 2014-12-30 Method of testing the activity of a potentially active substance to inhibit the enzymatic activity of phospholipase a2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0214490A FR2847267B1 (fr) 2002-11-19 2002-11-19 Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2

Publications (2)

Publication Number Publication Date
FR2847267A1 FR2847267A1 (fr) 2004-05-21
FR2847267B1 true FR2847267B1 (fr) 2006-07-28

Family

ID=32187745

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0214490A Expired - Lifetime FR2847267B1 (fr) 2002-11-19 2002-11-19 Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2

Country Status (6)

Country Link
US (2) US20040096925A1 (fr)
JP (3) JP2004166684A (fr)
KR (1) KR101172700B1 (fr)
CH (1) CH694107A5 (fr)
DE (2) DE10362194C5 (fr)
FR (1) FR2847267B1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019653A1 (de) * 2005-04-26 2006-11-02 Henkel Kgaa Pflanzenextrakte gegen Halitosis, Gingivitis oder Parodontitis
FR2892635B1 (fr) 2005-10-28 2012-11-09 Engelhard Lyon Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage
FR2916977A1 (fr) 2007-06-06 2008-12-12 Engelhard Lyon Sa STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE.
ES2700111T3 (es) 2007-06-28 2019-02-14 Basf Beauty Care Solutions France Sas Composición adelgazante
CN105816498A (zh) 2009-04-27 2016-08-03 玫琳凯有限公司 植物性抗痤疮制剂
FR2954702B1 (fr) 2009-12-31 2013-07-05 Basf Beauty Care Solutions F Agent stimulant l'expression de loxl
KR102773605B1 (ko) 2011-12-19 2025-02-25 마리 케이 인코포레이티드 피부톤 향상을 위한 식물 추출물의 조합물
FR2994387B1 (fr) 2012-08-13 2016-07-29 Basf Beauty Care Solutions France Sas Ingredient hydratant cosmetique ou pharmaceutique
FR2997406B1 (fr) 2012-10-25 2015-07-03 Basf Beauty Care Solutions F Polymere de hyaluronate et de glucomannane
FR3000488B1 (fr) 2012-12-27 2015-10-02 Basf Beauty Care Solutions F Nouveaux derives de l'acide sinapique et leurs utilisations cosmetiques ou pharmaceutiques
FR3003758B1 (fr) 2013-03-27 2015-07-17 Basf Beauty Care Solutions France Sas Utilisation cosmetique ou dermatologique d'un extrait de polygonum bistorta
FR3009786B1 (fr) 2013-08-23 2017-08-11 Basf Beauty Care Solutions France Sas Utilisation cosmetique ou dermatologique d'un extrait de quassia amara
FR3010314B1 (fr) 2013-09-12 2017-05-05 Basf Beauty Care Solutions France Sas Utilisation cosmetique ou dermatologique d'un extrait de tapirira guyanensis
US9849077B2 (en) 2014-03-10 2017-12-26 Mary Kay Inc. Skin lightening compositions
FR3026947B1 (fr) 2014-10-10 2017-12-08 Basf Beauty Care Solutions France Sas Activite deglycation d'une combinaison d'un extrait de salvia miltiorrhiza et de niacine et/ou de niacinamide
JP7032852B2 (ja) * 2014-11-29 2022-03-09 共栄化学工業株式会社 毛髪化粧料
FR3030275B1 (fr) 2014-12-23 2018-03-02 Basf Beauty Care Solutions France Sas Utilisation d'un extrait de lythrum salicaria
WO2016127319A1 (fr) * 2015-02-10 2016-08-18 深圳市新产业生物医学工程股份有限公司 Kit de réactifs utilisé pour la détection de la phospholipase a2 associée aux lipoprotéines, et procédé de préparation et application du kit de réactifs
FR3049859B1 (fr) 2016-04-12 2023-11-03 Basf Beauty Care Solutions France Sas Utilisation cosmetique d'un extrait de khaya senegalensis
FR3058641B1 (fr) 2016-11-17 2019-11-01 Basf Beauty Care Solutions France Sas Utilisation cosmetique, nutraceutique ou pharmaceutique preferentiellement dermatologique d'un extrait de feuilles de la plante lansium domesticum pour diminuer la pigmentation de la peau et/ou des annexes cutanees
FR3061015B1 (fr) 2016-12-23 2019-09-20 Basf Beauty Care Solutions France Sas Utilisation cosmetique d'un extrait de corchorus olitorius
FR3065876B1 (fr) 2017-05-05 2020-08-14 Basf Beauty Care Solutions France Sas Utilisation d'un extrait de nephelium lappaceum pour augmenter la fermete de la peau et/ou des muqueuses
FR3069162A1 (fr) 2017-07-24 2019-01-25 Basf Beauty Care Solutions France Sas Extrait aqueux de momordica cochinchinensis pour maintenir et/ou augmenter l'expression des kindlines de la peau et des muqueuses
FR3097127B1 (fr) 2017-10-03 2022-09-16 Basf Beauty Care Solutions France Sas Procédé d’utilisation d’un inhibiteur de Let-7b en cosmétique et/ou en nutraceutique
FR3071742B1 (fr) 2017-10-03 2020-07-10 Basf Beauty Care Solutions France Sas Procede d'utilisation d'un inhibiteur de let-7b en cosmetique et/ou en nutraceutique
KR102227399B1 (ko) * 2019-10-08 2021-03-15 이화여자대학교 산학협력단 내열성 신규 포스포리파아제 a2 및 포스포리파아제 a2 생산방법
FR3106756B1 (fr) 2020-01-30 2023-12-22 BASF Beauty Care Solutions France Utilisation cosmétique, nutraceutique ou dermatologique d'un extrait deTamarindus indicaL. et / ou d’une composition le comprenant
FR3110415B1 (fr) 2020-05-20 2023-07-14 Basf Beauty Care Solutions France Sas Utilisation d’un extrait d’adansonia digitatapour maintenir et / ou diminuer la communication bacterienne
FR3117340B1 (fr) 2020-12-15 2024-01-05 Basf Beauty Care Solutions France Sas Utilisation cosmétique, nutraceutique ou dermatologique d’une souche deLactobacillus crispatus et / ou d’une composition la comprenant
FR3133312B1 (fr) 2022-03-08 2024-07-19 Basf Beauty Care Solutions France Sas Utilisation cosmétique ou dermatologique de Sphingomonas glacialis et/ou d’une composition la comprenant
WO2023180661A1 (fr) 2022-03-23 2023-09-28 Basf Beauty Care Solutions France Sas Utilisation cosmetique ou dermatologique d'un extrait de dendrobium officinale pour maintenir et/ou augmenter l'epaisseur de la peau
CN116831962A (zh) 2022-03-23 2023-10-03 巴斯夫美容护理法国公司 铁皮石斛提取物用于维持和/或增加皮肤厚度的化妆或皮肤病学用途
FR3134010A1 (fr) 2022-03-30 2023-10-06 Basf Beauty Care Solutions France Sas Utilisation cosmétique, nutraceutique et/ou dermatologique d’une souche de Lactobacillus crispatus et/ou d’une composition la comprenant
JP2025520900A (ja) 2022-07-04 2025-07-03 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス カキョク（火棘，Ｐｙｒａｃａｎｔｈａ ｆｏｒｔｕｎｅａｎａ）抽出物の美容的又は皮膚科学的使用
FR3138039A1 (fr) 2022-07-21 2024-01-26 Basf Beauty Care Solutions France Sas Utilisation cosmétique ou dermatologique d’un extrait de Pyracantha fortuneana
FR3138615A1 (fr) 2022-08-02 2024-02-09 Basf Beauty Care Solutions France Sas Nouvelle utilisation cosmétique ou dermatologique d’un extrait de Gentiana crassicaulis
JP2025524118A (ja) 2022-07-26 2025-07-25 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス ゲンチアナ・クラッシカウリス（Ｇｅｎｔｉａｎａ ｃｒａｓｓｉｃａｕｌｉｓ）抽出物の新規な美容的又は皮膚科学的使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE145672T1 (de) * 1989-08-29 1996-12-15 Univ California Neue inhibitoren für hydrolytische enzyme und substrate und bestimmungsverfahren, selbige einschliessende verfahren und testsätze
WO1993019745A1 (fr) * 1992-04-01 1993-10-14 The University Of Virginia Patents Foundation Procede de traitement du cholera et de la colite associee au clostridium difficile
JP2691662B2 (ja) * 1992-07-08 1997-12-17 花王株式会社 化粧料
JP2764510B2 (ja) * 1992-12-28 1998-06-11 花王株式会社 美白化粧料
JP3529811B2 (ja) * 1993-06-30 2004-05-24 三省製薬株式会社 皮膚外用剤
JPH0733673A (ja) * 1993-07-19 1995-02-03 Taisho Pharmaceut Co Ltd テストステロン−５α−リダクターゼ阻害剤
JPH07126166A (ja) * 1993-10-29 1995-05-16 Sagami Chem Res Center ホスホリパ−ゼａ２阻害剤
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
JP3696271B2 (ja) * 1994-09-22 2005-09-14 花王株式会社 美白化粧料
JP3233813B2 (ja) * 1995-03-31 2001-12-04 株式会社マンダム チロシナーゼ生合成促進剤及び白髪改善用又は白髪防止用頭髪用化粧料並びに日焼け用化粧料
US6025178A (en) * 1997-03-28 2000-02-15 Eli Lilly And Company Human phospholipase A2 and related nucleic acid compounds
FR2757395B1 (fr) * 1996-12-20 1999-03-12 Dior Christian Parfums Utilisation d'un extrait de la plante davallia, dans les domaines cosmetique et pharmaceutique, notamment dermatologique
JP4676040B2 (ja) * 1997-07-31 2011-04-27 株式会社林原生物化学研究所 組成物
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
DE29717497U1 (de) * 1997-10-01 1999-02-04 Braun, Michaela, Dipl.-Ing., 52064 Aachen Kosmetischer Tee-Extrakt
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
WO2000002561A1 (fr) * 1998-07-13 2000-01-20 University Of South Florida Modulation de la voie de phospholipase a2 utilisee comme procede therapeutique
FR2787996B1 (fr) * 1998-12-30 2002-05-10 Dior Christian Parfums Composition cosmetique ou dermatologique contenant un actif stimulant la synthese de la proteine hsp 32 dans la peau et methode de traitement cosmetique
JP2000247830A (ja) * 1999-02-26 2000-09-12 Nagase & Co Ltd エラスターゼ阻害剤
JP2000319191A (ja) * 1999-03-05 2000-11-21 Takeda Chem Ind Ltd サイクリックｇｍｐ特異的ホスホジエステラーゼ阻害剤および性的機能障害改善薬
JP2000351723A (ja) * 1999-06-09 2000-12-19 Naris Cosmetics Co Ltd 皮膚外用剤
JP2001158728A (ja) * 1999-12-01 2001-06-12 Shiseido Co Ltd ヒアルロン酸産生促進剤および皮膚外用剤
WO2001042462A2 (fr) * 1999-12-08 2001-06-14 National University Of Singapore Nouveaux agents therapeutiques et prophylactiques et leurs procedes d'utilisation
FR2802818B1 (fr) * 1999-12-24 2002-08-30 Greentech Sa Procede d'obtention d'un extrait d'ecorce de bouleau, betula alba, et especes apparentees
JP2001192338A (ja) * 2000-01-11 2001-07-17 Pola Chem Ind Inc ストレスの悪影響からの回復促進剤及びそれを含有してなる皮膚外用剤
JP2001200237A (ja) * 2000-01-20 2001-07-24 Pokka Corp 紫外線吸収剤及びそれを含有した皮膚外用剤
JP2001220344A (ja) * 2000-02-09 2001-08-14 Ichimaru Pharcos Co Ltd 植物水蒸気蒸留水含有化粧料組成物
JP4726022B2 (ja) * 2000-03-28 2011-07-20 キッコーマン株式会社 抗アレルギー、抗炎症剤並びにこれを含有する医薬組成物、医薬部外品、化粧品、食品及び動物用飼料
JP2001348338A (ja) * 2000-06-06 2001-12-18 Noevir Co Ltd コラーゲン産生促進剤、及びこれを含有する老化防止用皮膚外用剤
WO2001095728A1 (fr) * 2000-06-13 2001-12-20 Fd Management, Inc. Composition cosmetique pour peau agressee par des conditions extremes
JP2002097149A (ja) * 2000-09-20 2002-04-02 Noevir Co Ltd 皮膚外用剤
WO2002031160A2 (fr) * 2000-10-10 2002-04-18 Bayer Aktiengesellschaft Regulation de l'enzyme de type a2 phospholipase humaine
JP2002193733A (ja) * 2000-12-25 2002-07-10 Kanebo Ltd 化粧料
DE10107323A1 (de) * 2001-02-16 2002-10-02 Bernd Gath Zusammensetzung zur Steigerung von Entgiftungs-Stoffwechselvorgängen
DE10131188B4 (de) * 2001-05-03 2005-06-16 Coletica, S.A. Verfahren zum Testen einer Substanz, die potentiell auf dem Gebiet der Lipolyse wirksam ist, und die hauptsächliche kosmetische Verwendung hiervon
JP4615796B2 (ja) * 2001-11-20 2011-01-19 株式会社ファンケル 刺激緩和組成物
DE10219139A1 (de) * 2002-04-29 2003-11-13 Sauer Pharma Gmbh & Co Kg Phytaminpräparat
JP2004075661A (ja) * 2002-06-18 2004-03-11 Shiseido Co Ltd 表皮基底膜ケアを特徴とする皮膚外用剤、皮膚基底膜構造形成促進剤および人工皮膚の製造方法
US20050186172A1 (en) * 2002-07-08 2005-08-25 Laboratoires Clarins, A Corporation Of France Cosmetic composition capable of fighting against skin aging
FR2841782B1 (fr) * 2002-07-08 2004-09-17 Clarins Lab Composition cosmetique capable de lutter contre le vieillissement cutane
JP2010539086A (ja) * 2007-09-07 2010-12-16 バイオノボ・インコーポレーテッド マメ科ファミリーのクズのエストロゲン性抽出物およびその使用
GB2483934A (en) * 2010-09-27 2012-03-28 Gary William Wheatley Botanical extracts obtained by subcritical water extraction

Also Published As

Publication number Publication date
FR2847267A1 (fr) 2004-05-21
JP2009108104A (ja) 2009-05-21
DE10320603A1 (de) 2004-06-09
JP2004166684A (ja) 2004-06-17
KR20040044076A (ko) 2004-05-27
DE10362194C5 (de) 2016-10-27
DE10362194B4 (de) 2008-11-13
JP5425489B2 (ja) 2014-02-26
CH694107A5 (fr) 2004-07-15
US20040096925A1 (en) 2004-05-20
KR101172700B1 (ko) 2012-08-09
JP2012224637A (ja) 2012-11-15
US20150110907A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
FR2847267B1 (fr) Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2
EP1496896A4 (fr) Inhibiteurs de l'activite akt
EP1496906A4 (fr) Inhibiteurs de l'activite de akt
EP1494675A4 (fr) Inhibiteurs de l'activite de akt
EP1620095A4 (fr) Inhibiteurs de l'activite akt
EP1536812A4 (fr) Methodes permettant de moduler l'activite du recepteur nucleaire fxr
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
NO20004219L (no) Inhibitorer av fosfolipaseenzymer
NO20004220L (no) Inhibitorer av fosfolipaseenzymer
EP1784175A4 (fr) Inhibiteurs de l'activite de akt
EP1737861A4 (fr) Inhibiteurs de l'activite d'akt
FR2833100B1 (fr) Procede de reconstitution d'une image d'un organe
ITMI20011987A0 (it) Procedimento e sistema basati su computer per l'analisi di misurazione di manufatti
EP1455182A4 (fr) Procede d'evaluation de defaillance et analyseur
EP1489174A4 (fr) Procede de modification des proprietes d'une proteine
FI20000111L (fi) Menetelmä paperinvalmistusprosessin analysoimiseksi ja sähkökemiallinen anturi nesteen analysoimiseksi
FR2852700B1 (fr) Procede et installation d'imagerie acousto-optique.
EP0994707A4 (fr) Inhibiteurs de l'activite enzymatique de naaladase
DK1456404T3 (da) Fremgangsmåde til at bestemme difibrotids biologiske aktivitet
FR2768544B1 (fr) Procede de detection d'activite vocale
EP1421210A4 (fr) Procede de detection de l'activite de la protease dans une cellule
EP1065494A4 (fr) Procede d'essai de durete d'une micro-region
EP1497450A4 (fr) Methodes d'identification de composes modulant l'activite enzymatique
FI20020584A7 (fi) Menetelmä havainnointialueen mittakaavan määrittämiseksi
EP1852442A4 (fr) Anticorps pour le dosage de l'activite adamts13 et procede de dosage de l'activite

Legal Events

Date Code Title Description
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20